ClinicalTrials.gg
CompletedNCT00724048HARTUpdated Aug 31, 2023Results posted

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

A Phase 2 interventional study of ACR16 and Placebo in Huntington Disease, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 28 sites in 2 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
17th of 90
227 · median 44
Started
2008
with 3 others
Phase 2
28 of 138
none open now
Registered
26th of 138
by date

Among the 138 studies in Huntington Disease with a site in United States, this one is the 17th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2008, is one of 28 in phase 2, and was the 26th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • Huntington Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written prior to any study related procedure, including consent to genotyping of the CYP2D6 gene.
  • Clinical features of HD, and a positive family history and/or the presence of ≥ 36 CAG repeats in the Huntington gene.
  • Male or female age ≥ 30 years.
  • Willing and able to take oral medication and to comply with the study specific procedures.
  • Ambulatory, being able to travel to the assessment center, and judged by the Investigator as likely to be able to continue to travel for the duration of the study.
  • Availability of a caregiver or family member to accompany the participant to two visits.
  • A sum of ≥ 10 points on the mMS at the screening visit.
  • For participants taking allowed antidepressants or other psychotropic medication , the dosing of medication must have been kept constant for at least 6 weeks before baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any antipsychotic medication (neuroleptics) within 8 weeks of baseline visit, or at any time point during the study period.
  • Use of tetrabenazine within 12 weeks of baseline visit, or at any time during the study period.
  • Treatment with any product within 4 weeks of baseline visit.
  • Use of tricyclic antidepressants or class I antiarrhythmics within 6 weeks of baseline visit, or at any time during the study period.
  • Use of concomitant medication that may lower the seizure threshold within 6 weeks of baseline visit, or at any time during the study period .
  • Use of metoclopramide within 12 weeks of baseline visit, or at any time during the study period.
  • Participants currently receiving deep brain stimulation (DBS).
  • Participants with a history of surgical procedures aiming to improve the symptoms of Huntington disease, such as neural transplantations, lesions of the central nervous system, infusions of neurotrophic agents or previous attempts of deep brain stimulation.
  • Participants previously randomized into this study.
  • A prolonged at Screening Visit (defined as a QTc interval of > 450 milliseconds [msec] for males or > 470 msec for females), or other heart conditions as judged by the investigator.
  • \<40 milliliters (mL)/minute (min) as measured at the screening visit.
  • Any clinically significant, abnormal, baseline laboratory result which in the opinion of the Investigator, affects the participant' suitability for the study or puts the participant at risk if he/she enters the study.
  • Clinically significant hepatic or renal impairment.
  • Participants with a known history of epilepsy or a history of febrile seizure(s) or seizure(s) of unknown cause.
  • Severe intercurrent illness, which, in the opinion of the Investigator, may put the participant at risk when participating in the trial or may influence the results of the trial or affect the subjects' ability to take part in the trial.
  • Alcohol and/or drug abuse as defined by , 4th Edition, Text Revision (DSM IV-TR) criteria for Substance Abuse - this includes the illicit use of cannabis within the last 12 months prior to Screening Visit
  • Participants with suicidal ideation as defined as a positive score on criteria for major depressive episode, item A9 on the DSM -IV-TR criteria for a Major Depressive Episode
  • Females who are pregnant or lactating or who intend to become pregnant during the study period.
  • Females who are of child bearing potential and not taking adequate precautions are excluded from the trial. (Females of taking acceptable contraceptive precautions can be included)
  • Known allergy to any ingredients of the trial medication or placebo
  • Any previous participation in a clinical study with ACR16.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
227 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive a placebo capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), placebo capsule will be taken twice daily (BID) as 2 separate doses.

    Other: Placebo

  • Experimental
    ACR16 10 mg BID

    Participants will receive ACR16 10 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 10 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 20 mg).

    Drug: ACR16

  • Experimental
    ACR16 22.5 mg BID

    Participants will receive ACR16 22.5 mg capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 22.5 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 45 mg).

    Drug: ACR16

  • Experimental
    ACR16 45 mg BID

    Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 45 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 90 mg).

    Drug: ACR16

Interventions

  • DrugACR16

    ACR16 will be administered per dose and schedule specified in the arm description.

    Also known as: pridopidine

  • OtherPlacebo

    Placebo matching to ACR16 will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12

    The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS included dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items were rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranged from 0 to 52, with higher scores indicating more severe motor impairment. The last observation carried forward (LOCF) method was used to generate an mMS score for each participant for Week 12 assessment.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Total Motor Score (TMS)

    The UHDRS Motor Assessment comprises 31 responses from the 15 items, where each response is rated on a 5-point scale from 0 (normal) to 4 (maximally abnormal). The Total Motor Score (TMS) is the sum of all the 31 responses with higher scores indicating more severe motor impairment than lower scores.

    Time frame: Basline, Week 12

  2. Number of Participants in Each of the Ratings of the Clinical Global Impression of Change (CGI-C) Scale

    The CGI-C was rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.

    Time frame: Week 12

  3. Change From Baseline in Stroop Word Reading Test

    The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Total UHDRS Behavioral Assessment Score

    The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score

    HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0-42. Lower change from baseline scores indicate improvement.

    Time frame: Baseline, Week 12

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to Week 14

07

Results

Posted Aug 31, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Started58565558
Received at least 1 dose of study drug58565558
Full analysis set58555558
Completed55515255
Not completed3533
Withdrew: Adverse event1110
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject1212
Withdrew: Investigator decision0010
Withdrew: Did not tolerate study drug0001
Withdrew: Other than specified1100

Outcome measures

PrimaryChange From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12

The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS included dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items were rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranged from 0 to 52, with higher scores indicating more severe motor impairment. The last observation carried forward (LOCF) method was used to generate an mMS score for each participant for Week 12 assessment.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12
units on a scalePlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12-1.40 ± 3.72-1.30 ± 3.33-2.49 ± 3.37-2.32 ± 3.72
Statistical analysis
  • Placebo vs ACR16 45 mg BID · ANCOVA · p = 0.078 · Mean difference (final values): -1.17 · 95% CI -2.47 to 0.13
  • Placebo vs ACR16 22.5 mg BID · ANCOVA · p = 0.084 (Hypothesis testing was completed only if ACR16 45 mg BID (90 mg) vs. placebo was significant.) · Mean difference (final values): -1.19 · 95% CI -2.53 to 0.16
  • Placebo vs ACR16 10 mg BID · ANCOVA · p = 0.982 (Hypothesis testing was completed only if ACR16 22.5 mg BID (45 mg) vs. placebo was significant.) · Mean difference (final values): -0.02 · 95% CI -1.35 to 1.32
SecondaryChange From Baseline in Total Motor Score (TMS)

The UHDRS Motor Assessment comprises 31 responses from the 15 items, where each response is rated on a 5-point scale from 0 (normal) to 4 (maximally abnormal). The Total Motor Score (TMS) is the sum of all the 31 responses with higher scores indicating more severe motor impairment than lower scores.

Time frame:
Basline, Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total Motor Score (TMS)
Units on a scalePlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Change From Baseline in Total Motor Score (TMS)-2.09 ± 8.31-1.92 ± 6.07-3.30 ± 6.91-4.61 ± 7.21
SecondaryNumber of Participants in Each of the Ratings of the Clinical Global Impression of Change (CGI-C) Scale

The CGI-C was rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants in Each of the Ratings of the Clinical Global Impression of Change (CGI-C) Scale
ParticipantsPlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Not assessed0112
Very much improved0124
Much improved8384
Minimally improved20141721
No change24312225
Minimally worse4451
Much worse1101
Very much worse0000
SecondaryChange From Baseline in Stroop Word Reading Test

The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · correct responses
Change From Baseline in Stroop Word Reading Test
correct responsesPlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Change From Baseline in Stroop Word Reading Test2.5 ± 13.03.7 ± 10.6-0.0 ± 12.72.8 ± 10.5
SecondaryChange From Baseline in Total UHDRS Behavioral Assessment Score

The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total UHDRS Behavioral Assessment Score
Units on a scalePlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Change From Baseline in Total UHDRS Behavioral Assessment Score-3.56 ± 8.51-3.24 ± 11.24-3.45 ± 10.10-6.19 ± 10.17
SecondaryChange From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score

HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0-42. Lower change from baseline scores indicate improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score
Units on a scalePlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score-1.04 ± 3.67-1.24 ± 4.57-0.95 ± 4.68-2.10 ± 5.68
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to Week 14
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BID
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)33302540

Adverse events

Collected over Baseline up to Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/58 (1.7%)22/58 (37.9%)
ACR16 10mg BID—0/56 (0%)18/56 (32.1%)
ACR16 22.5 mg BID—2/55 (3.6%)16/55 (29.1%)
ACR16 45 mg BID—3/58 (5.2%)30/58 (51.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboACR16 10mg BIDACR16 22.5 mg BIDACR16 45 mg BID
ConvulsionNervous system disorders0/580/561/550/58
DepressionPsychiatric disorders0/580/561/550/58
Suicidal ideationPsychiatric disorders0/580/561/550/58
Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/580/560/550/58
Adjustment disorderPsychiatric disorders0/580/560/551/58
Bipolar disorderPsychiatric disorders0/580/560/551/58
Testicular torsionReproductive system and breast disorders0/580/560/551/58
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboACR16 10mg BIDACR16 22.5 mg BIDACR16 45 mg BID
FallInjury, poisoning and procedural complications7/589/568/558/58
NauseaGastrointestinal disorders4/582/561/555/58
FatigueGeneral disorders5/581/562/552/58
DiarrhoeaGastrointestinal disorders3/583/564/552/58
Urinary tract infectionInfections and infestations1/581/560/554/58
ExcoriationInjury, poisoning and procedural complications4/581/562/551/58
DizzinessNervous system disorders0/580/560/554/58
DepressionPsychiatric disorders4/582/562/552/58
HeadacheNervous system disorders3/583/563/553/58
Huntington's choreaNervous system disorders2/583/562/553/58

Baseline characteristics

The full analysis set was defined as all randomized participants who received at least 1 dose of study drug and had undergone at least 1 clinical assessment post randomization.

Age, Continuous
Age, Continuous(years)PlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BIDTotal
Mean49.9 ± 10.654.0 ± 10.850.0 ± 10.550.3 ± 9.751.0 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BIDTotal
Female33322728120
Male25232830106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BIDTotal
Hispanic/Latino02024
American Indian or Alaskan Native00000
Black or African American21216
White56525254214
More than 1 Race00112
Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)
Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)(units on a scale)PlaceboACR16 10 mg BIDACR16 22.5 mg BIDACR16 45 mg BIDTotal
Mean17.19 ± 6.4916.96 ± 6.1814.18 ± 5.0316.22 ± 6.3916.15 ± 6.13
08

Study locations

28 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of California
    San Diego, California 92161, United States
  • Colorado Neurological Institute
    Littleton, Colorado 80120, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287-7281, United States
  • Massachusetts General Hospital
    Charlestown, Massachusetts 02129, United States
  • Struthers Parkinson's Center
    Saint Louis Park, Minnesota 55426, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • North Shore-LIJ Health System
    Manhasset, New York 11030, United States
  • University of Rochester
    Rochester, New York 14618, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Ohio State University Parkinson's Center
    Columbus, Ohio 43210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • University of Tennessee Health Science Center
    Memphis, Tennessee 38163, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9036, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Booth Gardner Parkinson's Care Center
    Kirkland, Washington 98034, United States
  • University of Alberta Glenrose Rehab Hospital
    Edmonton, Alberta T5G 0B7, Canada
  • University of British Columbia
    Vancouver, British Columbia V6T 2B5, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • The Centre for Addiction and Mental Health
    Markham, Ontario L6B1C9, Canada
  • Parkinsons and Neurodegenerative Disorders Clinic
    Ottawa, Ontario K1G4G3, Canada
  • Hotel-Dieu Hospital-CHUM
    Montreal, Quebec H2L4M1, Canada
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2008 to primary completion in Jul 2010, 21 months.

Results were first posted in Aug 2023, 13 years 1 month after primary completion. A results delay was requested in Feb 2013.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2008
First posted
Jul 29, 2008
StartActual
Oct 24, 2008
Primary completionActual
Jul 26, 2010
CompletionActual
Jul 26, 2010
Results delay requested
Feb 19, 2013
Results first posted
Aug 31, 2023
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00724048
Responsible party
Sponsor
First posted
Jul 29, 2008
Start date
Oct 24, 2008
Primary completion
Jul 26, 2010
Completion
Jul 26, 2010
Results posted
Aug 31, 2023
Last update
Aug 31, 2023

Study contacts

Teva Medical Expert
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion